Patents
Literature
15 results about "Picornavirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A picornavirus is a virus belonging to the family Picornaviridae, a family of viruses in the order Picornavirales. Vertebrates, including humans, serve as natural hosts. Picornaviruses are nonenveloped viruses that represent a large family of small, cytoplasmic, plus-strand RNA (~7.5kb) viruses with a 30-nm icosahedral capsid. Its genome does not have a lipid membrane. Picornaviruses are found in mammals and birds. There are currently 80 species in this family, divided among 35 genera. Notable examples are Enterovirus (including Rhinovirus and Poliovirus), Aphthovirus, Cardiovirus, and Hepatovirus genera. The viruses in this family can cause a range of diseases including paralysis, meningitis, hepatitis and poliomyelitis. Picornaviruses are in Baltimore IV class. Their genome single-stranded (+) sense RNA is what functions as mRNA after entry into the cell and all viral mRNA synthesized is of genome polarity. The mRNA encodes RNA dependent RNA polymerase. This polymerase makes complementary minus strands of RNA, then uses them as templates to make more plus strands. So, an overview of the steps in picornavirus replication are in order: attachment, entry, translation, transcription/genome replication (one and the same process), assembly and exit.
Methods and compositions for generating an immune response against a picornavirus
PCT designated stageWO2026096440A1SsRNA viruses positive-sensePeptide/protein ingredientsPicornavirusImmunity response
Vaccine compositions for protecting a subject against diseases caused by viral pathogens of the Picornaviridae family are disclosed. These vaccines comprise nucleic acids encoding the capsid polyprotein (P1 polyprotein) mixed with the viral 3C protease that processes the P1 polyprotein, and encapsulated within nanoparticle carriers. Methods of preventing, reducing, inhibiting, or delaying the symptoms of an infection caused by a viral pathogen, or of inducing an immune response against a viral pathogen in a subject are provided. Methods of making the vaccines are also described.
Owner:TIBA BIOTECH LLC
INTRACELLULAR DELIVERY OF THERAPEUTIC CARGOS AND VIRAL RNAs BY ENGINEERED SALMONELLA
The disclosure provides an engineered Salmonella typhimurium comprising a first heterologous nucleic acid encoding a first polypeptide that causes bacterial lysis, a second heterologous nucleic acid encoding a second polypeptide that causes vacuolar lysis, and a third heterologous nucleic acid encoding a virus, wherein the virus comprising a picornavirus. Further disclosed is a method of using the engineered bacteria for treating a tumor in a subject.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
A method for identifying whether a sample to be tested is infected with SGDV and a special primer pair thereof
The application discloses a method for identifying whether a sample to be detected is infected with a shrimp glass disease virus (SGDV) and a special primer pair thereof. The inventor of the application finds a new small ribonucleic acid virus SGDV in Penaeus vannamei Boone, and the nucleotide sequence of the virus is shown in SEQ ID NO: 3. Experiments prove that a primer pair composed of a primer F shown in SEQ ID NO: 1 and a primer R shown in SEQ ID NO: 2 can accurately identify whether the sample to be detected is infected with the SGDV. The application has important application value, and helps us to deepen the understanding of virus diversity, provides guidance for the breeding of the Penaeus vannamei Boone and has important significance for preventing infectious diseases in aquaculture.
Owner:BEIJING UNIV OF CHEM TECH
Peptidomimetics for the treatment of coronavirus and picorna virus infections
Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and / or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
Owner:EMORY UNIVERSITY
Oncolytic viruses as therapeutic agents for treating cancer
PendingJP2026506348AOrganic active ingredientsSsRNA viruses positive-senseCancer cellPharmaceutical drug
The present invention relates to compositions and methods for treating cancer utilizing oncolytic viruses, components thereof, and / or derivatives thereof. In particular, the present invention relates to modified picornaviruses that contain alterations in one or more of their capsid proteins that confer enhanced binding ability to cancer cells.
Owner:イムヴィルクス ピーティーワイ リミテッド
Broad-spectrum antiviral agents against 3C or 3C-like proteases from picornavirus superclusters: picornaviruses, calicivires, and coronaviruses
Owner:KANSAS STATE UNIV RES FOUND +2
3c protease inhibitors of picorna viruses including enterovirus d68 and human rhino viruses
Compounds and treatment methods with dipeptidyl compounds exhibiting antiviral activity and / or inhibition of viral replication against viruses by inhibiting 3CL protease, particularly those belonging to picornavirus, the compounds having a formula:(I) or (I)*.
Owner:KANSAS STATE UNIV RES FOUND +1
Antiviral 1,3-dioxoindene compounds
To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.
Owner:NOVARTIS AG +2
Broad spectrum antivirals against coronavirus
Compounds exhibiting antiviral activity and / or inhibition of viral replication against viruses, particularly those belonging to the picornavirus-like supercluster, including coronavirus having a formula: (I) where X comprises a cyclic moiety, R2 is a branched or unbranched alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amino acid side chain, bicyclic or tricyclic side chain, combinations, and substituted forms thereof, and Z is selected from the group consisting of C1-C6 hydroxyalkyl, aldehydes, alpha-ketoamides, and bisulfite salts, and in particular —CH2OH, —CHO, —CH(0H)S03−Na+, and -[0(C=0)Rw]S03−Na+.
Owner:THE WICHITA STATE UNIV +2
Heteroatom containing peptidomimetics targeting viral proteases
Disclosed herein are methods for preventing or treating a viral infection, e.g., coronavirus, enterovirus, norovirus, picornavirus, rhinovirus, and / or a herpes virus infection. In certain embodiments, this disclosure relates to peptidomimetic heterocyclic compounds and pharmaceutical compositions comprising the same for uses in methods disclosed herein.
Owner:EMORY UNIVERSITY
Broad-spectrum antiviral drugs against coronaviruses
Compounds that exhibit antiviral activity and / or inhibit viral replication against viruses, in particular viruses belonging to the picornavirus-like supergroup, including coronaviruses, having the following formula: (I) wherein X comprises a cyclic moiety, R2 is a branched or unbranched alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amino acid side chain, bicyclic or tricyclic side chain, combinations and substituted forms thereof, and Z is selected from the group consisting of C1-C6 hydroxyalkyl, aldehyde, alpha-ketoamide, and bisulfite, and in particular -CH2OH, -CHO, -CH(OH)SO3 ‑ Na + , and -[0(C=0)R w ]SO3 ‑ Na + .
Owner:KANSAS STATE UNIV RES FOUND +2
Anti-viral compounds
InactiveJP2025166040AOrganic active ingredientsAntiviralsEnzyme Inhibitor AgentPharmaceutical medicine
To provide compositions and kits of antiviral agents having different mechanisms of action for treating or preventing viral infections such as COVID-19 (also known as SARS-CoV-2) and for reducing medical complications related to COVID-19 viral disease.SOLUTION: A pharmaceutical composition for treating COVID-19 is provided, comprising: a first antiviral agent consisting of a picornavirus 3C protease inhibitor or a pharmaceutically acceptable salt thereof in a therapeutically effective amount; a second antiviral agent consisting of ritonavir or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and having a different mechanism of action; and a third antiviral agent selected from a group consisting of dexamethasone and remdesivir.SELECTED DRAWING: None
Owner:グレッグジョンエムエイチ
Production of RNA polynucleotides encoding picornavirus
PendingUS20250281556A1SsRNA viruses positive-senseMicroencapsulation basedPicornavirusPolynucleotide
The present disclosure relates to production of recombinant RNA molecules encoding an oncolytic virus genome, such as a picornavirus, with native 5′ end of the viral genome utilizing ribozymes. The present disclosure further relates to the design of corresponding DNA template and the use of the recombinant RNA molecules and / or corresponding particles for the treatment and prevention of cancer.
Owner:LIFEEDIT THERAPEUTICS INC
Oncolytic viruses as therapeutic agents for treatment of cancer
The present invention relates to compositions and methods for treating cancer using oncolytic viruses, components thereof, and / or derivatives thereof. In particular, the present invention relates to modified picornaviruses comprising changes in one or more of its capsid proteins that confer enhanced binding capacity to cancer cells.
Owner:IMMVIRX PTY LTD
Alternative Splicing Polypeptides and Their Applications
ActiveCN119410600BOxidoreductasesVector-based foreign material introductionNicotiana tabacumAdonis vernalis L.
The present invention provides alternative splicing polypeptides and their applications. The alternative splicing polypeptide of the present invention is a polypeptide composed of 23 amino acids at the N-terminus of HBFD from Adonis amurensis, which can achieve specific splicing in tobacco and realize the tandem expression of multiple proteins in a single expression cassette. The alternative splicing polypeptide of the present invention has better splicing specificity in plants than the 2A self-cleaving polypeptide of picornavirus reported by predecessors, which is beneficial to reducing the occurrence of non-specific splicing. The alternative splicing polypeptide of the present invention is a protein splicing element derived from plants, which is beneficial to improving the application value of the tandem expression technology of multiple proteins based on a single expression cassette in plant bioreactors.
Owner:TOBACCO RESEARCH INSTITUTE OF CHINESE ACADEMY OF AGRICULTURAL SCIENCES (QINGZHOU TOBACCO RESEARCH INSTITUTE OF CHINA NATIONAL TOBACCO COMPANY)